KMT2A and acute myeloid leukemia: With this as the goal, we determined and highlight hitherto unreported effects of SNDX-50469, an orally bioavailable, investigational MI, concordantly altering accessible chromatin of active enhancers/promoters with the transcriptome and protein expressions in AML cell lines and patient-derived (PD) AML cells, including phenotypically defined AML stem/progenitor cells with MLL1-r or mtNPM1 [15, 16, 18].